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Objective: To compare efﬁcacy and tolerability between different regimens of rifaximin vaginal tablets and a
placebo for treatment of bacterial vaginosis. Methods: In a prospective study carried out at 13 sites in 3 Euro-
pean countries between August 2009 and October 2010, White, non-pregnant, premenopausal women with
bacterial vaginosis were randomly assigned to receive rifaximin at 100 mg for 5 days (100 mg/5 days),
25 mg/5 days, or 100 mg/2 days, or placebo. Women were assessed at 7–10 and 28–35 days. Diagnosis
and cure were based on Amsel criteria and Nugent score. Fisher exact test was used to compare cure rates.
Results: Among 114 women recruited, 103 were evaluable for drug efﬁcacy. Therapeutic cure rate at ﬁrst
follow-up was higher in the rifaximin 25 mg/5 days (48%, P=0.04), 100 mg/2 days (36.0%), and 100 mg/
5 days (25.9%) groups than in the placebo group (19.0%). At second follow-up, therapeutic cure rate was
28.0%, 14.8%, and 4.0% in the respective groups versus 7.7% in the placebo group. No difference in adverse
events was observed. Conclusion: Rifaximin at 25 mg/5 days showed better therapeutic cure rates and main-
tenance of therapeutic cure after 1 month versus placebo. All treatment regimens were well tolerated.
EudraCT number: 2009-011826-32.
© 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.1. Introduction
Bacterial vaginosis, one of the most frequent vaginal infections
[1,2], is an ecologic disorder of the vaginal microbiota, characterized
by a massive overgrowth of mixed commensal anaerobic and/or
microaerophilic ﬂora replacing protective lactobacilli [3–5]. Although
perceived as a mild medical problem, bacterial vaginosis is associated
with an awful disease burden and with adverse obstetric and gyneco-
logic outcomes [6–9].
Current standard antibiotic therapies—that is, oral or vaginal
metronidazole or clindamycin—have similar clinical cure rates of
60%–90% at 1 month [10]; however, relief is often short-lived, and re-
currence occurs in 15%–30% of women within 1–3 months and 50%–
70% of women within 6–12 months [11]. Moreover, these drugs are
systemically absorbed and are not infrequently associated with ad-
verse effects such as nausea, abdominal cramping, unpleasant taste
[12], and vulvovaginal candidiasis [13]. Severe pseudomembranous
colitis has also been reported [14].s and Gynecology, Heilig Hart
.: +32 16809500; fax: +32
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eration of Gynecology and Obstetrics.Rifaximin (Alfa Wassermann, Bologna, Italy)—a virtually non-
absorbed antibiotic derivative of rifamycin with broad-spectrum
antibacterial activity covering Gram-positive, Gram-negative, aerobic,
and anaerobic bacteria—has been used to treat gastrointestinal infec-
tions as an oral formulation and, being negligibly absorbed, presents a
good safety proﬁle [15]. Because rifaximin is also active against many
organisms responsible for genital infections, local use of this antibiotic
for the treatment of bacterial vaginosis has been suggested [16].
The aim of the VARIANT 1 (vaginosis rifaximin treatment) study
was to evaluate efﬁcacy and tolerability of 2 doses and 2 treatment
durations (100 mg for 5 days, 25 mg for 5 days, and 100 mg for
2 days) of rifaximin vaginal tablets versus a placebo for the treatment
of bacterial vaginosis.2. Materials and methods
In an early Phase 2, multicentric, randomized, double-blind,
placebo-controlled study conducted at 13 study sites in 3 European
countries, women affected with bacterial vaginitis were enrolled be-
tween August 14, 2009, and October 19, 2010, in accordance with
the Declaration of Helsinki and Good Clinical Practice guidelines.
The protocol was approved by the independent ethics committeesPublished by Elsevier Ireland Ltd. All rights reserved.
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consent before being enrolled in the study.
White, non-pregnant, premenopausal women, aged 18–50 years,
were eligible for the study. In accordance with the US Food and
Drug Administration (FDA) deﬁnition, bacterial vaginosis was diag-
nosed on the basis of the combined presence of at least 3 out of 4
Amsel criteria [17] and a Gram stain Nugent score of 4 or higher
[18]. Participating women were required to abstain from intercourse
during the 5-day treatment period and for 3 days before the follow-
up visits, to avoid the use of intravaginal products, including douches,
sprays, tampons, spermicides, gels, foams and diaphragms, and to
adopt an adequate contraceptive method during the study.
Women were excluded from the study if they were pregnant or
breast-feeding, anticipated menses at screening or follow-up visits,
or had received systemic or vaginal antimicrobial therapy in the
2 weeks before the study. Additional exclusion criteria were dysplas-
tic ﬁndings on a cervical Papanicolaou smear or having had cervical
cryo-, laser- or conization therapy in the past 3 months; clinical evi-
dence of genital herpes; any chronic or debilitating disease; history
of drug or alcohol abuse; mental illness; known hypersensitivity to
rifaximin; and clinically relevant abnormal laboratory values. All par-
ticipants were required to test negative for Neisseria gonorrhoeae and
Chlamydia trachomatis by PCR, Candida albicans by microscopy, and
Trichomonas vaginalis by culture or by PCR if negative by wet mount.
The study included a screening visit (V1), a randomization visit (V2),
and 2 follow-up visits (V3, V4). Patients were evaluated for study eligi-
bility at V1, and up to 7 days later were randomized at V2 by an interac-
tive voice response system in a 1:1:1:1 ratio to receive a daily rifaximin
vaginal tablet of 100 mg for 5 days (100 mg/5 days); a daily rifaximin
vaginal tablet of 25 mg for 5 days (25 mg/5 days); a daily rifaximin
vaginal tablet of 100 mg for 2 days, followed by daily placebo for
3 days (100 mg/2 days); or a daily placebo vaginal tablet for 5 days
(placebo). The medication was dispensed by the investigator in accor-
dancewith a computer-generated random allocation sequence (SAS re-
lease 9.2; SAS Institute, Cary, NC, USA) prepared by a statistician who
was not blind to the treatment regimen. Treatment regimens were
also stratiﬁed by patient history of bacterial vaginosis (ﬁrst bacterial
vaginosis episode versus recurrent bacterial vaginosis).
Both investigator and patient were unaware of the treatment dis-
pensed because the placebo was indistinguishable from the active sub-
stance, having the same weight, appearance, and color. Patients were
instructed to insert 1 tablet of the study drug intravaginally at bedtime
and then again daily at the same time for 5 days. Furthermore, they re-
ceived a diary card to record intake and time of study medication, local
subjective tolerability, and use of concomitant medications. At V3,
7–10 days after the end of therapy, patients who did not show thera-
peutic cure were withdrawn from the study as a treatment failure and
received standard treatment, whereas patients showing cure attended
V4, the second follow-up visit, 28–35 days after the end of treatment.
Efﬁcacy and safety assessments were performed at each follow-up
visit; tests for N. gonorrhoeae, C. trachomatis, C. albicans and T. vaginalis
were performed only if clinically indicated.
The primary efﬁcacy endpoint was therapeutic cure of bacterial
vaginosis (the combined presence of ≤2 Amsel criteria and a Nugent
score of ≤3) at V3. Secondary efﬁcacy endpoints were clinical cure
according to Amsel criteria (≤2 criteria) at V3, bacteriologic cure
according to Nugent score (≤3) at V3, andmaintenance of therapeutic
cure at V4.
Bacterial vaginosis diagnostics at V1, V3, and V4 comprised assess-
ment for Amsel criteria (presence of vaginal discharge, vaginal pH
measurement, microscopic examination of fresh vaginal ﬂuid for the
presence of clue cells, and “whiff test”with 10% potassiumhydroxide),
and Gram stain for Nugent score performed in an external laboratory
not linked to the investigator site. Safety and adverse effects were
evaluated on the basis of local objective signs (vaginal erythema,
edema, petechial hemorrhages, ulcerations), subjective symptoms(vaginal pain, burning, itching, assessed on a 0–3 severity score),
vital signs, physical and pelvic examination ﬁndings, and routine
laboratory parameters.
NQueryAdvisor version 6.0 (Statistical Solutions, Munich, Germany)
was used to estimate sample size on the basis of planned conﬁrmative
comparisons of the rifaximin treatment groups versus the placebo
group with respect to therapeutic cure rates. The power estimation
was based on a 2-sided Fisher exact test. Assuming a cure rate of 10%
in the placebo group [19], a sample size of 22 patients per group
would provide at least 80% power for each single comparison, resulting
in a required overall sample size of 88 patients. Assuming a 20% rate of
screening failures and a 20% drop-out rate, we planned to screen 140
patients to attain 112 randomized patients (28 patients per group).
The primary analysis of efﬁcacy was performed on the full analysis
set (FAS), which consisted of all patients who were randomized, took
at least the ﬁrst 3 consecutive doses of study medication, and
attended at least 1 visit after randomization with available efﬁcacy
data. Analyses of primary and secondary endpoints for supportive
and sensitivity purposes were also performed on the per protocol
set, consisting of all patients who had completed the 5-day treatment
according to the treatment schedule without protocol violations, to
assess their inﬂuence on the study results.
Descriptive 95% Clopper–Pearson 2-sided conﬁdence intervals of
cure rates were calculated for each treatment group to enable further
explorative comparisons among the different rifaximin dosage
groups. Analyses of the secondary efﬁcacy endpoints were performed
in a manner similar to analysis of the primary endpoint and were
purely descriptive. Safety analysis was based on the safety evaluation
set, comprising all patients who received at least 1 dose of the study
medication. Safety variables, that is adverse events, local objective
and subjective tolerability, laboratory evaluations, vital signs, physical
examination ﬁndings, and gynecologic signs and symptoms were
analyzed via descriptive statistics.
Statistical analyses were performed using SAS version 9.2 (SAS
Institute). Comparisons of the cure rates among individual active
treatment groups, as well as between the pooled group of women
receiving any dose of rifaximin and those receiving placebo, were
performed using a 2-sided Fisher exact test. A P value of less than
0.05 was taken to be signiﬁcant.
3. Results
Among 149 patients screened, 35 did not meet the inclusion
criteria and were withdrawn before randomization. Of the 114 pa-
tients randomized, 106 proceeded to use the studymedication (safety
evaluation set), and 103 were evaluable for efﬁcacy (FAS). The ﬂow of
patients through the study is shown in Fig. 1.
The demographic characteristics of the participants by treatment
group are reported in Table 1. No relevant differences among the
groups were detected at baseline. Approximately half of the patients
in all groups reported bacterial vaginosis as a ﬁrst episode, and
there was an even prevalence of recurrent bacterial vaginosis
among all 4 groups (Table 1).
Analysis of the primary efﬁcacy endpoint in the FAS showed that
the therapeutic cure rate at V3 was higher in the rifaximin 25 mg/
5 days (48.0%, P=0.04), rifaximin 100 mg/2 days (36.0%), and
rifaximin 100 mg/5 days (25.9%) groups than in the placebo group
(19.0%) (Fig. 2). FAS results were conﬁrmed by analysis based on
the per protocol set. Subgroup analysis of the primary endpoint strat-
iﬁed by history of bacterial vaginosis showed a higher cure rate
among patients with “recurrent bacterial vaginosis” than among pa-
tients with a “ﬁrst episode of bacterial vaginosis” for all rifaximin
groups. Among women with a ﬁrst episode, those treated with the
rifaximin 25 mg/5 days regimen responded better (therapeutic cure
rate, 41.7%) than women treated with other rifaximin regimens or
placebo (therapeutic cure rate, 14%–25%; P=0.4) (Table 2).
Assessed for eligibility = 149 
Not meeting inclusion criteria = 35
Analyzed = 27
Protocol violation =  1
Study discontinued = 20
Treatment failure = 20
Allocated to rifaximin 100 mg/5 days = 28
Received rifaximin 100 mg/5 days = 28 
Allocated to rifaximin 25 mg/5 days = 29  
Received rifaximin 25 mg/5 days = 26
Withdrawal of informed consent  = 1
Lost to follow-up after V2 = 2
Allocation
Follow-Up at 28-35 days
Follow-Up at 7-10 days
Randomized = 114
Enrollment
Allocated to rifaximin 100 mg/2 days = 29 
Received rifaximin 100 mg/2 days = 26
Withdrawal of informed consent  = 1
Lost to follow-up after V2 = 2
Allocated to placebo = 28
Received placebo = 26
Lost to follow-up after V2 = 2
Allocation Allocation
Analyzed = 25
Protocol violation =  1
Study discontinued = 12
Treatment failure = 12
Analyzed = 25
Protocol violation =  1
Study discontinued = 16
Treatment failure = 16
Analyzed = 26
Study discontinued = 21
Treatment failure = 20
Protocol violation = 1
Follow-Up at 7-10 days Follow-Up at 7-10 days
Analyzed = 7 Analyzed = 12
Lost to follow-up = 1
Analyzed = 9 Analyzed = 5
Follow-Up at 28-35 days Follow-Up at 28-35 days
Fig. 1. Flow of participants through the study. Among 149 patients who were screened, 35 patients failed screening and were withdrawn before randomization, 114 patients were randomized, 106 patients received the study medication, and
103 patients underwent evaluation for drug efﬁcacy.
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Table 1
Characteristics of participants by randomized treatment group.a
Characteristic Rifaximin,
100 mg/5 d
(n=27)
Rifaximin,
25 mg/5 d
(n=25)
Rifaximin,
100 mg/2 d
(n=25)
Placebo
(n=26)
White 27 (100.0) 25 (100.0) 25 (100.0) 26 (100.0)
Age, y 35.1±8.92 36.4±9.28 37.2±8.01) 35.3±10.80
Weight, kg 63.21±13.24 64.90±14.98 62.05±13.22) 63.85±10.33
Height, cm 166.0±6.37 167.0±5.14 164.8±7.34) 167.0±6.39
BMI 22.94±4.72 23.24±5.10 22.85±4.65) 22.86±3.24
History of STDs 4 (14.3) 1 (3.8) 1 (3.8) 2 (7.7)
First episode of BV 14 (50.0) 12 (46.2) 12 (46.2) 14 (53.8)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the
square of height in meters); BV, bacterial vaginosis; STDs, sexually transmitted
diseases.
a Values are given as mean±SD or number (percentage).
Table 2
Therapeutic cure rate at V3 of ﬁrst BV episode and recurrent BV subgroups by treat-
ment group.a
Patient subgroup Rifaximin
100 mg/5 d
Rifaximin
25 mg/5 d
Rifaximin
100 mg/2 d
Placebo
First BV episode
No. of women 14 12 12 14
Cure rate 2 (14.3) 5 (41.7) 3 (25.0) 3 (21.4)
Recurrent BV
No. of women 13 13 13 12
Cure rate 5 (38.5) 7 (53.8) 6 (46.2) 2 (16.7)
Abbreviations: BV, bacterial vaginosis; V3, visit 3 (ﬁrst follow-up visit).
a Values are given as number (percentage) unless otherwise indicated.
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on Amsel criteria) were 80.0% with rifaximin 25 mg/5 days, 72.0%
with rifaximin 100 mg/2 days, 66.7% with rifaximin 100 mg/5 days,
and 42.3% with placebo. Comparison of cure rates between the place-
bo group and rifaximin 25 mg/5 days, rifaximin 100 mg/2 days, and
the pooled rifaximin group gave P values of 0.001, 0.05, and 0.01,
respectively. Bacteriologic cure rates (based on Nugent score) were
lower than those evaluated by Amsel criteria for all treatment groups,
and identical to results obtained for the primary efﬁcacy endpoint
(Figs. 3 and 4). Nevertheless, the cure rate based on Nugent score
was higher in the rifaximin 25 mg/5 days group than in the placebo
group (P=0.04). The percentage of patients maintaining therapeutic
cure at V4 was highest for the rifaximin 25 mg/5 days group (28.0%),
followed by the 100 mg/5 days (14.8%), 100 mg/2 days (4.0%), and
placebo (7.7%) groups (Fig. 5).
In total, 80 treatment-related adverse events were reported by 40
patients (37.7%). The percentage of patients with treatment-related ad-
verse events was highest in the placebo group (46.2%), followed by the
rifaximin 100 mg/5 days (35.7%), rifaximin 25 mg/5 days (34.6%), and
rifaximin 100 mg/2 days (7.7%) groups. Local symptoms (vulvovaginal
burning, vulvovaginal pain, and vulvovaginal pruritus) were the most
frequently reported adverse events and were equally distributed
among the groups. Most adverse events in each group were of mild or
moderate intensity. Evaluation of objective and subjective local symp-
toms showed that all 4 treatments were well tolerated.
No bacterial or protozoan superinfections were reported during
the study, but 9 patients showed vulvovaginal candidiasis: 4 in the
rifaximin 25 mg/5 days group, 2 in the 100 mg/5 days group, 2 in
the 100 mg/2 days group, and 1 in the placebo group. During the
follow-up, vaginal inﬂammation was reported for 1 patient treated
with rifaximin 100 mg/5 days, and vulvovaginal burning sensationp=0.04
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Fig. 2. Therapeutic cure rate, deﬁned on the basis of the co-primary parameters Amsel
criteria and Nugent score, in each treatment group.and discomfort for 1 patient treated with rifaximin 25 mg/5 days.
The adverse events causing the most severe discomfort were
vulvovaginal pruritus (1 patient taking rifaximin 100 mg/5 days), di-
arrhea (2 patients taking rifaximin 25 mg/5 days), and gastrointesti-
nal symptoms and headache (1 patient taking rifaximin 25 mg/
5 days). None of patients experienced serious adverse events, or ad-
verse events leading to study withdrawal.
Analyses of routine laboratory assessments, vital signs, physical
examination ﬁndings, and gynecologic data did not identify any note-
worthy changes over the course of the study for any treatment group.
4. Discussion
Both clindamycin andmetronidazole have proven effectiveness for
the clinical symptoms of bacterial vaginosis (i.e. Amsel criteria), but
their long-term efﬁcacy is hampered by negative effects on the normal
vaginal microﬂora because their spectrum of activity also affects
lactobacilli [20]. As a consequence, 15%–30% of women with bacterial
vaginosis experience a recurrence within 1 month of treatment, and
an overall cure rate of less than 50% after 3 months has been reported
[11]. The main contributors to this high rate of bacterial vaginosis
recurrence are the presence of metronidazole-resistant Atopobium
vaginae, a prominent indicator of recurrence risk [21], and a bacterial
bioﬁlm of Gardnerella vaginalis and A. vaginae, which is unresponsive
to standard treatment [22], covering the vaginal mucosa. A correct ap-
proach to bacterial vaginosis, use of appropriate parameters to evalu-
ate short- and mid-term efﬁcacy, safety evaluation, management of
ﬁrst disease presentation, and control of recurrences are important
factors to be considered in the development of a newdrug for bacterial
vaginosis treatment [23]. The FDA requires that patients should be
evaluated by a combination of Amsel criteria and Nugent score in clin-
ical studies of new drugs for bacterial vaginosis [24].
The ideal objective of a treatment for bacterial vaginosis should be
a combination of, ﬁrst, eradication of all bacterial vaginosis-related
bacteria; second, no development of antibacterial resistance; third,
the re-emergence of protective Lactobacillus spp.; and fourth,p=0.001
p=0.05 p=0.01
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Fig. 3. Cure rate deﬁned as the clinical cure rate (Amsel criteria) in each treatment
group.
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Fig. 4. Cure rate deﬁned as the bacteriologic cure rate (Nugent score) in each treatment
group.
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25 mg/5 days showed a trend for better efﬁcacy compared with
both the placebo and other rifaximin groups with respect to the
therapeutic cure rate evaluated by Amsel criteria and Nugent score
together, in addition to the cure rate evaluated by Amsel criteria
alone, and with respect to the maintenance of therapeutic cure. In
particular, because vaginal tablets containing 25 mg of rifaximin
were more effective than those containing 100 mg in eliminating
abnormal bacterial morphotypes and enhancing the detection of
lactobacilli as assessed by Nugent score, we propose that a 25-mg
dosage might support lactobacilli recolonization and growth, whereas
100 mg of rifaximin, being also active against lactobacilli, might be a
too high dosage to re-establish the normal ﬂora.
Regarding treatment duration, the 100 mg/2 days dosage of
rifaximin seemed to be more effective than the 100 mg/5 days dos-
age at ﬁrst follow-up, but the rate of recurrence at second follow-up
was higher for the 100 mg/2 days dosage than for the 100 mg/
5 days dosage. Considering the fact that length of treatment is of pri-
mary importance in eradicating pathogens, a high-dosage, short-term
treatment might be less effective in eradicating abnormal bacteria
and allowing recolonization by normal protective lactobacilli, com-
pared with a lower-dosage, longer-term treatment. The clinical cure
rates achieved with rifaximin (80.0% in the 25 mg/5 days group,
72.0% in the 100 mg/2 days group, and 66.7% in the 100 mg/5 days
group) were similar to those reported for metronidazole and
clindamycin [25]. In addition, all 3 rifaximin treatment regimens
were safe and well tolerated.
The higher than expected remission rate in the placebo group
(19%) is an unexpected and bothersome ﬁnding. Because we followed
FDA guidelines [24], the inclusion of some women with intermediate
ﬂora (Nugent score 4–6) might have led to the inclusion of patients
who did not have genuine “full-blown” bacterial vaginosis, resulting
in both a spontaneous cure rate that was above average and a lack
of beneﬁcial effect of the study drug.0
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Fig. 5.Maintenance of therapeutic cure at visit 4 (second follow-up) in each treatment
group.In conclusion, although the results of the present proof-of-concept
study need to be conﬁrmed in future clinical trials, a treatment regi-
men of 25-mg rifaximin vaginal tablets administered over 5 days
promises to have cure rates equal to those of other standard treat-
ments for bacterial vaginosis, but with negligible adverse effects and
less effect on the lactobacillary ﬂora.Acknowledgments
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